1. Articles in category: Virotherapy

    1-13 of 13
    1. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus

      Alerts Cancer Therapy: Preclinical Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus Mohanraj Ramachandran , Di Yu , Matheus Dyczynski , Sathishkumar Baskaran , Lei Zhang , Aleksei Lulla , Valeria Lulla , Sirle Saul , Sven Nelander , Anna Dimberg , Andres Merits , Justyna Leja-Jarblad and Magnus Essand Mohanraj Ramachandran PDF Abstract Background: Glioblastoma multiforme and high-risk neuroblastoma are cancers with poor outcome. Immunotherapy in the form of neurotropic oncolytic viruses is a promising therapeutic approach for these malignancies. Here we evaluate the oncolytic capacity of the neurovirulent and partly IFNβ-resistant Semliki Forest virus (SFV)-4 in glioblastoma multiformes ...

      Read Full Article
    2. Junction opening protein boosts cancer-killing effect of oncolytic virus

      Junction opening protein boosts cancer-killing effect of oncolytic virus

      ( Mary Ann Liebert, Inc./Genetic Engineering News ) A new study shows that the anti-tumor effect of oncolytic virus therapy is significantly greater in mice when the virus is genetically modified to express a junction opening (JO) protein, which helps the cancer-killing agent better penetrate solid tumors. The potential for JO to improve cancer therapy with various types of oncolytic viruses is described in Human Gene Therapy.

      Read Full Article
    3. The Future of Oncolytic Virotherapy with Reovirus

      The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low efficacy, toxicity, and treatment-resistant tumor subclones. Oncolytic viral therapy offers a novel therapeutic strategy that has the potential to dramatically improve clinical outcomes. Reovirus, a double-stranded benign human RNA virus, is a leading candidate for therapeutic development and currently in phase III trials.

      Read Full Article
    4. Viral Therapy in Melanoma Clinical Trial Led by Rutgers Cancer Institute Physician-Scientist is Approved by FDA

      The U.S. Food and Drug Administration has approved an immunotherapy known as T-VEC that was the focus of a phase III melanoma clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.

      Read Full Article
    5. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

      Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

      Neuro Oncol. 2015 Sep 26;

      Authors: Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, Shim K, Peterson T, Parney IF, Short S, Selby P, Ilett E, Melcher A, Vile R

      Read Full Article
    6. Oncolytics Biotech® Inc. Collaborators Present Data from Clinical Study in Multiple Myeloma

      -- All Evaluable Patients to Date See Evidence of an Objective Response; Treatment Combination Associated with Statistically Significant Upregulation of PD-L1--

      CALGARYSept. 25, 2015 /CNW/ - Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC) (NASDAQ: ONCY) today announced that Dr. D.W. Sborov and colleagues made a poster presentation at the 15th International Myeloma Workshop (IMW). The poster presentation, entitled "Combination Carfilzomib and the Viral Oncolytic Agent REOLYSIN® in Patients with Relapsed Multiple Myeloma: A Pilot Study Investigating Viral Proliferation," discloses initial findings from a pilot study (NCI-9603) in patients with relapsed or refractory multiple myeloma treated using the combination of carfilzomib ...

      Read Full Article
    7. Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain.

      Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain.

      Pediatr Surg Int. 2015 Aug 23;

      Authors: Takenouchi A, Saito K, Saito E, Saito T, Hishiki T, Matsunaga T, Isegawa N, Yoshida H, Ohnuma N, Shirasawa H

      Abstract PURPOSE: With current treatment regimens, high-risk neuroblastoma (NB) remains largely incurable. Oncolytic viral therapy uses replication-competent viruses, like Sindbis virus (SINV), to kill cancers.

      Read Full Article
    8. Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells.

      Abstract: Neuroblastoma (NB) is the most common extracranial solid tumor that originates from multipotent neural crest cells. NB cell populations which express embryonic stem cell-associated genes have been identified and shown to retain a multipotent phenotype. However, whether somatic reprogramming of NB cells can produce similar stem-cell like populations is unknown. Here, we sought to reprogram NB cell lines using an integration-free Sendai virus vector system.

      Read Full Article
    9. Rabbit Virus Improves Bone Marrow Transplants, Kills Some Cancer Cells

      Rabbit Virus Improves Bone Marrow Transplants, Kills Some Cancer Cells

      Newswise — University of Florida Health researchers have discovered that a rabbit virus can deliver a one-two punch, killing some kinds of cancer cells while eliminating a common and dangerous complication of bone marrow transplants. For patients with blood cancers such as leukemia and multiple myeloma, a bone marrow transplant can be both curative and perilous.

      Read Full Article
    10. World first as viral immunotherapy for skin cancer shows patient benefit in Phase III trial

      World first as viral immunotherapy for skin cancer shows patient benefit in Phase III trial

      A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown. It is the first time that a Phase III trial of viral immunotherapy has definitively shown benefit for patients with cancer.

      Read Full Article
      Mentions: Immunotherapy
    1-13 of 13
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles